NCT06227962Enrolling by invitation
Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors
Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors (8-35 Years): The Role of Cancer Treatment and Repeated Anesthesia
Source: ClinicalTrials.gov · Last updated 4 Dec 2025
Brief summary (registry, in English)
A retrospective crosssectional observational study of the effects of oncological treatment and frequent general anesthesia on neuropsychological development, psychosocial functioning (in terms of anxiety, depression, peer relations, perceived cognitive functioning and potential trauma) and health related quality of life in children and young adults who were treated or screened for retinoblastoma.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 240 (estimated)
- First submitted
- 20 Dec 2023
- Start date
- 26 Oct 2023
- Primary completion date
- 30 Oct 2026
- Lead sponsor
- Amsterdam University Medical Center
- Diseases
- Childhood cancers
- NCT number
- NCT06227962
What you commit to
- Study type: Observational
- Planned participants: 240
- From 26 Oct 2023 to the primary completion date, 30 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Rb diagnostic trajectory, treatment and follow-up at another hospital or before the founding of the Dutch Retinoblastoma Expertise Center in 1991. With exception of Rb survivors (diagnosed \>1991) who apart from treatment at the Dutch Retinoblastoma Center also required specialized treatment (such as radiation) at another center: they are illegible for inclusion.
Other illness
- Having an active, uncontrolled psychiatric illness,
Other
- Pre-existing documented developmental delay and/or severe cognitive impairments (IQ \<70),
Who the study is looking for
- Rb diagnosis, (main) treatment and follow-up of Rb patients and -survivors, or Rb screening took place at the Dutch Retinoblastoma Expertise Center of the Amsterdam University Medical Center,
- Rb survivor or former Rb risk carriers is between 8 and 35 years old,
- Average understanding of the Dutch language.
- Being a caregiver of a Rb survivor or Rb risk carrier that have been diagnosed and receive(d) (main) treatment and follow-up or screening at the Dutch Retinoblastoma Expertise Center of the Amsterdam University Medical Center,
- The related Rb survivor or Rb risk carrier is \< 12 years old,
- Average understanding of the Dutch language.
Age in the registry: 6 months to 35 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam University Medical Center Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.